We have demonstrated that bioresorbable vascular scaffold (BVS) for ACC/AHA type C lesions was associated with higher risks of long-term target lesion revascularization (TLR) and target lesion failure (TLF). We determined the specific time after which higher risks of BVS for type C lesions are reduced in a longer-term follow-up. We analyzed data of 457 patients (59±12 years, 87% male) with 714 BVS implanted for 529 lesions and a median follow-up of 56.4 (48.6-62.6) months. Patients with BVS for at least one type C lesion (N=177) at index intervention and all non-type C lesions (N=280) were compared for TLF (cardiac death, target vessel myocardial infarction, TLR). We specified the interactions between the non-type C versus type C group and the event-free survival times dichotomized at 24, 30, 32, 33, 36, and 39 months respectively. The type C group had more multivessel disease (86% versus 65%, p<0.001), left anterior descending artery treated (68% versus 53%, p=0.002), intravascular imaging used (48% vs. 25%, p<0.001), and BVS (2.3±0.9 vs. 1.1±0.3, p<0.001) implanted with a longer total length (57±21 vs. 29±8mm, p<0.001). The TLR or TLF was higher (both log-rank p<0.05) in the type C than in the non-type C group. However, the risks of TLR (hazard ratio: 3.6, 95% CI=1.1-11.6) and TLF (hazard ratio: 3.8, 95% CI=1.2-12.1) for type C lesions only remained higher until 24 months post-BVS implantation. BVS provides a longer-term advantage, particularly for type C lesions with the majority requiring long stenting.